Abstract
Introduction Rheumatoid arthritis (RA) is an auto-immune disease which causes irreversible damage to tissue and cartilage within synovial joints. Rapid diagnosis and treatment with disease-modifying therapies is essential to reduce inflammation and prevent joint destruction. RA is a heterogeneous disease, and many patients do not respond to front-line therapies, requiring escalation of treatment onto biologics, of which TNF inhibitors (TNF-i) are the most common.
Objectives/Methods In this study we determined whether serum metabolomics, using nuclear magnetic resonance (NMR) and Fourier transform infrared (FTIR) spectroscopy, could discriminate RA blood sera from healthy human controls and whether serum metabolomics could be used to predict response or non-response to TNF inhibitor (TNF-i) therapy.
Results NMR spectroscopy identified 35 metabolites in RA sera, with acetic acid being significantly lower in RA sera compared to healthy controls (HC, FDR<0.05). PLS-DA modelling identified 2-hydroxyisovalericacetic acid, acetoacetic acid, mobile lipids, alanine and leucine as important metabolites for discrimination of RA and HC sera by 1H NMR spectroscopy (averaged 83.1% balanced accuracy, VIP score >1). FTIR spectroscopy identified a significant difference between RA and HC sera in the 1000-1200 cm-1 spectral area, representing the mixed region of carbohydrates and nucleic acids (FDR<0.05). Sera from RA patients who responded to TNF-i were significantly different from TNF-i non-responder sera in the 1600-1700 cm-1 region (FDR<0.05).
Conclusion We propose that NMR and FTIR serum metabolomics could be used as a diagnostic tool alongside current clinical parameters to diagnose RA and to predict whether someone with severe RA will respond to TNF-i.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a Versus Arthritis and Masonic Charitable Foundation PhD scholarship (No. 22193) and a Versus Arthritis Career Development Fellowship (No. 21430).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the NRES Committee North West (Greater Manchester West, Manchester, UK, Ref: 11/NW/0206) for the collection of sera from people with RA, and the University of Liverpool Central Research Ethics Committee (Ref: 1672) for the collection of sera from healthy controls (HC). All participants gave written, informed consent in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
